Yellow fever vaccine

References

• World Health Organization. Progress in the control of yellow fever. Wkly Epidemiol. Rec. 80, 50–54 (2005).
   PubMedGoogle Scholar
• Robertson SE, Hull BP, Tomori O et al. Yellow Fever: a decade of reemergence. JAMA 276, 1157–1162 (1996).
   PubMed Web of Science ®Google Scholar
• Monath TP. Epidemiology of yellow fever: current status and speculations on future trends. In: Factors in the Emergence of Arbovirus Diseases. Saluzzo J-F, Dodet B (Eds), Elsevier, Paris, France, 143–156 (1997).
   Google Scholar
• Theiler M, Smith HH. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65, 787–800 (1937).
   PubMedGoogle Scholar
• Barrett ADT. Yellow fever vaccines. Biologicals 25, 17–25 (1997).
   PubMed Web of Science ®Google Scholar
• Monath TP. Yellow fever vaccine. In: Vaccines. (4th Edition) Plotkin S, Orenstien W (Eds). WB Saunders, PA, USA, 1095–1176 (2001).
   Google Scholar
• Monath TP. Yellow fever vaccines: the success of empiricism, pitfalls of application, and transition to molecular vaccinology. In: Vaccinia, Vaccination and Vaccinology: Jenner, Pasteur and their Successors. Plotkin S, Fantini M (Eds), Elsevier, Paris, France, 157–182 (1996).
   Google Scholar
• Smith HH, Penna HA, Paoliello A. Yellow fever vaccination with cultured virus (17D) without immune serum. Am. J. Trop. Med. Hyg.18,437–468 (1938).
   Google Scholar
• Brès P, Koch M. Production and testing of the WHO yellow fever primary seed lot 213–77 and reference batch 168–73. In: WHO Expert Committee on Biological Standardization, 36th Report. World Health Organization, Geneva, Switzerland, Tech Rep Ser No. 745: Annex 6, 113 (1987).
   Google Scholar
• Fox JP, Lennette EH, Manso C et al. Encephalitis in man following vaccination with 17D yellow fever virus. Am. J. Hyg. 36, 117–142 (1942).
   Google Scholar
• Fox JP, Penna HA. Behavior of 17D yellow fever virus in rhesus monkeys. Relation to substrain, dose and neural or extraneural inoculation. Am. J. Hyg. 38, 152–172 (1943).
   Google Scholar
• United Nations Relief and Rehabilitation Administration (UNRRA). Standards for the manufacture and control of yellow fever vaccine. Epidem. Inform. Bull. 1, 365 (1945).
   Google Scholar
• Fox JP, Kossobudzki SL, Da Chuma JF. Field studies of the immune response to 17D yellow fever virus. Am. J. Hyg. 38, 113–138 (1943).
   Google Scholar
• World Health Organization. Annex 9. Requirements for yellow fever vaccine. Addendum 1987. WHO Tech. Rep. Ser. 771, 208 (1988).
   Google Scholar
• Fox JP, Manso C, Penna HA, Pará M. Observations on the occurence of icterus in Brazil following vaccination against yellow fever. Am. J. Hyg. 36, 68–116 (1942).
   Google Scholar
• Sawyer WA, Meyer KF, Eaton MD et al. Jaundice in Army personnel in western region of United States and its relation to vaccination against yellow fever. Am. J. Hyg. 40, 35–107 (1944).
   Google Scholar
• Seeff LB, Beebe GW, Hoofnagle JH et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the US Army. N. Engl. J. Med. 316(16), 965–970 (1987).
   PubMed Web of Science ®Google Scholar
• Harris RJC, Dougherty RM, Biggs PM et al. Contaminant viruses in two live virus vaccines produced in chick cells. J. Hyg. (Lond.) 64(1), 1–7 (1966).
   PubMedGoogle Scholar
• Waters TD, Anderson PS Jr, Beebe GW et al. Yellow fever vaccination, avian leukosis virus, and cancer risk in man. Science 177, 76–77 (1972).
   PubMedGoogle Scholar
• Weiss RA. Adventitious viral genomes in vaccines but not in vaccinees. Emerg. Infect. Dis. 7, 153–154 (2001).
   PubMedGoogle Scholar
• Hussain AI, Shanmugam V, Switzer WM et al. Lack of evidence of endogenous avian leukosis virus and endogenous avian retrovirus transmission to measles, mumps, and rubella vaccine recipients. Emerg. Infect. Dis. 7, 66–72 (2001).
   PubMed Web of Science ®Google Scholar
• Levenbook IS, Pelleu LJ, Elisberg BL. The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and historical examination. J. Biol. Stand. 15, 305–313 (1987).
   PubMedGoogle Scholar
• Rice CM, Lenches EM, Eddy SR et al. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229, 726–733 (1985).
   PubMed Web of Science ®Google Scholar
• Dupuy A, Despres P, Cahour A et al. Nucleotide sequence comparison of the genome of two 17D-204 yellow fever vaccines. Nucleic. Acids Res. 17(10), 3989 (1989).
   PubMedGoogle Scholar
• Post PR, Duarte dos Santos CN, Carvalho R et al. Heterogeneity in envelope protein sequence and N-linked glycosylation among yellow fever virus vaccine strains. Virology 188(1), 160–167 (1992).
   PubMedGoogle Scholar
• Duarte dos Santos CN, Post PR, Carvalho R et al. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res. 35(1), 35–41 (1995).
   PubMedGoogle Scholar
• Dos Santos CN, Post PR, Carvalho R, Ferreira II, Rice CM, Galler R. Complete nucleotide sequence of yellow fever vaccine strains 17D and 17D-213. Virus Res. 35, 35–41 (1995).
   PubMedGoogle Scholar
• Hahn CH, Dalrymple JM, Strauss JH, Rice CM. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc. Natl Acad. Sci. USA 84(7), 2019–2023 (1987).
   PubMed Web of Science ®Google Scholar
• Liprandi F. Isolation of plaque variants differing in virulence from the 17D strain of yellow fever virus. J. Gen. Virol. 56, 363 (1981).
   PubMedGoogle Scholar
• Ryman KD, Xie H, Ledger TN, Campbell GA et al. Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Virology 230, 376–380 (1997).
   PubMedGoogle Scholar
• Pugachev KV, Ocran SW, Guirakhoo F et al. Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing. Vaccine 20, 996–999 (2002).
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Rice CM. Molecular biology of Flaviviruses. Adv. Virus Res. 59, 23–61 (2003).
   PubMed Web of Science ®Google Scholar
• Heinz FX, Allison SL. Flavivirus structure and membrane fusion. Adv. Virus Res. 59, 63–97 (2003).
   PubMed Web of Science ®Google Scholar
• Modis Y, Ogata S, Clements D et al. Structure of the dengue virus envelope protein after membrane fusion. Nature 427, 307–308 (2004).
   PubMedGoogle Scholar
• Hurrelbrink RJ, McMinn PC. Molecular determinants of virulence: the structural and functional basis for flavivirus attenuation. Adv. Virus Res. 60, 1–42 (2003).
   PubMedGoogle Scholar
• Arroyo J, Guirakhoo F, Fenner S et al. Molecular basis for attenuation of neurovirulence of a yellow fever/Japanese encephalitis (ChimeriVax™-JE) viral vaccine. J. Virol. 75, 934–942 (2001).
   PubMed Web of Science ®Google Scholar
• Ryman KD, Ledger TN, Campbell GA et al. Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. Virology 244(1), 59–65 (1998).
   PubMed Web of Science ®Google Scholar
• Chambers TJ, Nickells M. Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone. J. Virol. 75(22), 10912–10922 (2001).
   PubMed Web of Science ®Google Scholar
• Jennings AD, Gibson CA Miller BR et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J. Infect. Dis.169(3),512–518 (1994).
   PubMed Web of Science ®Google Scholar
• van Der Most RG, Murali-Krishna K, Ahmed R, Strauss JH. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue-specific CD8 T-cell response. J. Virol. 74(17), 8094–8101 (2000).
   PubMed Web of Science ®Google Scholar
• Schlesinger JJ, Chapman S, Nestorowicz A et al. Replication of yellow fever virus in the mouse central nervous system: comparison of neuroadapted and non-neuroadapted virus and partial sequence analysis of the neuroadapted strain. J. Gen. Virol. 77, 1277–1285 (1996).
   PubMedGoogle Scholar
• Hasegawa H, Yoshida M, Shiosaka T et al. Mutations in the envelope protein of Japanese encephalitis virus affect entry into cultured cells and virulence in mice. Virology 1912, 158–165 (1992).
   Google Scholar
• Ryman KD, Xie H, Ledger TN et al. Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Virology 230(2), 376–380 (1997).
   PubMedGoogle Scholar
• Holtzmann H, Stiasny K, Ecker M et al. Characterization of monoclonal antibody-escape mutants of tick-borne encephalitis virus with reduced neurovirulence. J. Gen. Virol. 78, 31–37 (1997).
   PubMedGoogle Scholar
• Khromykh AA, Sedlak PL, Westaway EG. Trans-complementation analysis of the flavivirus Kunjin NS5 gene reveals an essential l role for translation of its N-terminal half in RNA replication. J. Virol. 73, 9247–9255 (1999).
   PubMed Web of Science ®Google Scholar
• Kummerer BM, Rice CM. Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles. J. Virol. 76, 4773–4784 (2002).
   PubMed Web of Science ®Google Scholar
• Chambers TJ, Weir RC, Grakpoui A et al. Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc. Natl Acad. Sci. USA 87, 8898–8902 (1999).
   Google Scholar
• Xie H, Ryman HD, Campbell GA et al. Mutation in NS5 protein attenuates mouse neurovirulence of yellow fever 17D vaccine virus. J. Gen. Virol. 79(Pt. 8), 1895–1899 (1998).
   PubMedGoogle Scholar
• Men R, Bray M, Clark D et al. Dengue type 4 virus mutants containing deletions in the 3´ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J. Virol. 70, 3930–3937 (1996).
   PubMed Web of Science ®Google Scholar
• Markoff L, Pang X, Houng H-S et al. Derivation and characterization of a dengue type 1 host range restricted mutant virus that is attenuated and highly immunogenic in monkeys. J. Virol. 76, 3318–3328 (2002).
   PubMed Web of Science ®Google Scholar
• Bredenbeek PJ, Kooi EA, Lindenbach B et al. A stable full-length cDNA clone and the role of conserved RNA elements in flavivirus replication. J. Gen. Virol. 84, 1261–1268 (2003).
   PubMed Web of Science ®Google Scholar
• Proutski V, Gaunt MW, Gould EA et al. Secondary structure of the 3´-untranslated region of yellow fever virus: implications for virulence, attenuation, and vaccine development. J. Gen. Virol. 78, 1543–1549 (1997).
   PubMedGoogle Scholar
• Tesh RB, Guzman H, da Rosa AP et al. Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J. Infect. Dis.183(10), 1431–1436 (2001).
   PubMedGoogle Scholar
• Xiao SY, Zhang H, Guzman H, et al. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus). II. Pathology. J. Infect. Dis. 183(10), 1437–1444 (2001).
   PubMed Web of Science ®Google Scholar
• McArthur MA, Suderman MT, Mutebi J-P et al. Molecular characterization of a hamster viscerotropic strain of yellow fever virus. J. Virol. 77, 1462–1468 (2003).
   PubMed Web of Science ®Google Scholar
• Dunster LM, Wang H, Ryman KD et al. Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. Virology 261(2), 309–318 (1999).
   PubMedGoogle Scholar
• Smith HH, Penna HA, Paoliello A. Yellow fever vaccination with cultured virus (17D) without immune serum. Am. J. Trop. Med. Hyg.18,437–468 (1938).
   Google Scholar
• Sweet BH, Wisseman CJ Jr, Kitaoka M. Immunological studies with group B arthropod-borne viruses. II. Effect of prior infection with Japanese encephalitis virus on the viremia in human subject following administration of 17D yellow fever vaccine. Am. J. Trop. Med. Hyg.11,562–569 (1962).
   Web of Science ®Google Scholar
• Reinhardt B, Jaspert R, Niedrig M et al. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J. Med. Virol. 56(2), 159–167 (1998).
   PubMed Web of Science ®Google Scholar
• Saluzzo JF, Monath TP, Cornet M et al. Comparaison de différentes techniques pour la détection du virus de la fièvre jaune dans les prélièvements humains et les lots de moustiques: intérêt d’une méthode rapide de diagnostic par elisa. Ann. Inst. Pasteur. Virol. 136E, 115 (1985).
   Google Scholar
• Monath TP, Guirakhoo F, Nichols R et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase II clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis. 188(8), 1213–1230 (2003).
   PubMed Web of Science ®Google Scholar
• Monath TP, Brinker KR, Chandler FW et al. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the necrosis of B-cell areas of lymph nodes and spleen. Am. J. Trop. Med. Hyg. 30, 431–443 (1981).
   PubMedGoogle Scholar
• Brandler S, Brown N, Ermak TH et al. Replication of chimeric yellow fever virus-dengue serotype 1–4 virus vaccine strains in dendritic and hepatic cells. Am. J. Trop. Med. Hyg.72,74–81 (2005)
   PubMed Web of Science ®Google Scholar
• Wu S-JL, Grouard-Vogel G, Sun W et al. Human skin Langerhans cells are targets of dengue virus infection. Nature Med. 6(7), 816–820 (2000).
   PubMed Web of Science ®Google Scholar
• Cannon DA, Dewhurst F, Meers PD. Mass vaccination against yellow fever by scarification with 17D strain vaccine. Ann. Trop. Med. Parasit. 51(3), 256–263 (1957).
   PubMedGoogle Scholar
• Dean CH, Alarcon JB, Waterston AM et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese Encephalitis (ChimeriVaxTM-JE) in non-human primates. Hum. Vaccines (2005) (In Press).
   PubMedGoogle Scholar
• Johnston LJ, Halliday GM, King NJC. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. J. Invest. Dermatol. 114(3), 560–568 (2000).
   PubMed Web of Science ®Google Scholar
• Hamberger JF, Chen W, Myers GA et al. Biodistribution of ChimeriVax™-West Nile vaccine following subcutaneous administration to cynomolgus macaques. Am. J. Trop. Med. Hyg.71(Suppl.), 70 (2004).
   Google Scholar
• Tigertt W, Berge T, Gochenour WS, Gleiser C. Experimental yellow fever. Trans. NY Acad. Sci. 22, 323–333 (1960).
   Google Scholar
• Smithburn KC, Mahaffy AF. Immunization against yellow fever. Am. J. Trop. Med. 45, 217–226 (1945).
   Google Scholar
• Sabin A. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1(1), 30–50 (1952).
   PubMedGoogle Scholar
• David-West TS. Concurrent and consecutive infection and immunization with yellow fever and UGMP-359 virus. Arch. Virol. 48(1), 21–28 (1975).
   PubMedGoogle Scholar
• Stephen EL, Sammons ML, Pannier WL et al. Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J. Infect. Dis. 136(1), 122–126 (1977).
   PubMedGoogle Scholar
• Fredericksen BL, Smith M, Katze MG, Shi P-Y, Gale M Jr. The host response to West Nile virus infection limits viral spread through the activation of the interferon regulatory factor 3 pathway. J. Virol. 78(14), 7737–7747 (2004).
   PubMed Web of Science ®Google Scholar
• Wheelock EF, Sibley W. Circulating virus, interferon and antibody after vaccination with the 17-D strain of yellow-fever virus. N. Engl. J. Med. 273, 194–198 (1965).
   PubMedGoogle Scholar
• Bonnevie-Nielsen V, Heron I, Monath TP, Calisher CH. Lymphocytic 2´, 5´ -oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clin. Diag. Lab. Immunol. 2(3), 302–306 (1995).
   PubMedGoogle Scholar
• Arroyo JI, Apperson SA, Cropp CB et al. Effect of human γ interferon on yellow fever virus infection. Am. J. Trop. Med. Hyg.38(3), 647–650 (1988).
   PubMedGoogle Scholar
• Li K, Ferreon JC, Nakamura M et al. Immune evasion by hepatitis virus NS3/4A protease-mediated cleavage of the Toll-like receptor 2 adaptor protein TRIF. Proc. Soc. Natl Acad. Sci. USA 102, 2992–2997 (2005).
   PubMed Web of Science ®Google Scholar
• King NJC, Shresthra B, Kesson AM. Immune modulation by flaviviruses. Adv. Virus Res. 60, 121–155 (2003).
   PubMed Web of Science ®Google Scholar
• Bauer JH. The duration of passive immunity in yellow fever. Am. J. Trop. Med. Hyg.11,451 (1931).
   Google Scholar
• Davis NC. On the use of immune serum at various intervals after the inoculation of yellow fever virus into rhesus monkeys. J. Immun. 26, 361 (1934).
   Google Scholar
• Brandriss MW, Schlesinger JJ, Walsh EE et al. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J. Gen. Virol. 67, 229 (1986).
   PubMed Web of Science ®Google Scholar
• Gould EA, Buckley A, Barrett ADT et al. Neutralizing (54K) and non-neutralizing (54K and 58K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J. Gen. Virol. 67, 591 (1986).
   PubMed Web of Science ®Google Scholar
• Pan CH, Chen HW, Huang HW, Tao MH. Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell response. J. Virol. 75, 11457–11463 (2001).
   PubMed Web of Science ®Google Scholar
• Schlesinger JJ, Brandriss MW, Cropp CB et al. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J. Virol. 60(3), 1153–1155 (1986).
   PubMed Web of Science ®Google Scholar
• Putnak JR, Schlesinger JJ. Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b. J. Gen. Virol. 71, 1697–1702 (1990).
   PubMed Web of Science ®Google Scholar
• Monath TP, Nichols R, Archambault WT et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX™ and YF-VAX®) in a Phase III multicenter, double-blind clinical trial. Am. J. Trop. Med. Hyg.66(5), 533–541 (2002).
   PubMed Web of Science ®Google Scholar
• Belmusto-Worn VE, Sanchez JL, McCarthy K et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax™ and YF-VAX®) in healthy infants and children in Peru. Am. J. Trop. Med. Hyg. 72(2), 189–197 (2005).
   PubMed Web of Science ®Google Scholar
• Pfister M, Kursteiner O, Hilfiker H et al. Immunogenicity and safety of Berna-YF compared with two other 17D yellow fever vaccines in a Phase 3 clinical trial. Am. J. Trop. Med. Hyg.72(3), 339–346 (2005).
   PubMed Web of Science ®Google Scholar
• Lang J, Zuckerman J, Clarke P et al. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am. J. Trop. Med. Hyg. 60, 1045 (1999).
   PubMed Web of Science ®Google Scholar
• Monath TP. Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans. Am. J. Epidemiol. 93, 122 (1971).
   PubMedGoogle Scholar
• Diamond MS, Sitati EM, Friend LD et al. A critical role for induced IgM in the protection against West Nile virus infection. J. Exp. Med. 198, 1853–1862 (2003).
   PubMed Web of Science ®Google Scholar
• Gollins SW, Poterfield JS. Flavivirus infection enhancement in macrophages: an electron microscopic study of viral cellular entry. J. Gen. Virol. 66, 1969–1982 (1985).
   PubMed Web of Science ®Google Scholar
• Butrapet S, Kimura-Kuroda J, Zhou DS et al. Neutralizing mechanism of a monoclonal antibody against Japanese encephalitis virus glycoprotein E. Am. J. Trop. Med. Hyg.58,389–398 (1998).
   PubMedGoogle Scholar
• Clarke DH. Antigenic analysis of certain group B arthropodborne viruses by antibody absorption. J. Exp. Med. 111, 21–32 (1960).
   PubMed Web of Science ®Google Scholar
• Mutebi J-P, Wang H, Li L et al. Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa. J. Virol. 75(15), 6999–7008 (2001).
   PubMedGoogle Scholar
• Mason RA, Tauraso NM, Spertzel RO et al. Yellow fever vaccine: Direct challenge of monkeys given graded doses of 17D vaccine. Appl. Microbiol. 25(4), 539–544 (1973).
   PubMedGoogle Scholar
• Monath TP, Craven RB, Muth DJ, Trautt CJ, Calisher CH, Fitzgerald SA. Limitations of the complement-fixation test for distinguishing naturally acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areas. Am. J. Trop. Med. Hyg.29(4), 624–634 (1980).
   PubMed Web of Science ®Google Scholar
• Wong SJ, Boyle RH, Demarest VL et al. Immunoassay targeting nonstructural protein 5 to differentiate West Nile virus infection from dengue and St. Louis encephalitis virus infections and from flavivirus vaccination. J. Clin. Microbiol. 41(9), 4217–4223 (2003).
   PubMed Web of Science ®Google Scholar
• Martin M, Tsai TF, Cropp CB et al. Multisystemic illness in elderly recipients of yellow fever vaccine: report of four cases. Lancet 358, 98–104 (2001).
   PubMed Web of Science ®Google Scholar
• Poland JD, Calisher CH, Monath TP et al. Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull. World Health Organ. 59(6), 895–900 (1981).
   Google Scholar
• Bonnevie-Nielsen V, Heron I, Monath TP, Calisher CH. Lymphocytic 2´, 5´-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clin. Diag. Lab. Immunol. 2(3), 302–306 (1995).
   PubMedGoogle Scholar
• Wisseman CL Jr, Sweet BH. Immunological studies with group B arthropod-borne viruses. III. Response of human subjects to revaccination with 17D strain yellow fever vaccine. Am. J. Trop. Med. Hyg.11,570–575 (1962).
   PubMedGoogle Scholar
• Monath TP, McCarthy K, Bedford P et al. Clinical proof of principle for ChimeriVax™: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20(7–8), 1004–1018 (2002).
   PubMed Web of Science ®Google Scholar
• Wisseman CL Jr, Sweet BH, Kitaoka M, Tamiya T. Immunological studies with group b arthropod-borne viruses. I. Broadened neutralizing antibody spectrum induced by strain 17D yellow fever vaccine in human subjects previously infected with Japanese encephalitis virus. Am. J. Trop. Med. Hyg.11,550–561 (1962).
   PubMedGoogle Scholar
• Kayser M, Klein H, Paasch I, Pilaski J, Blenk H, Heeg K. Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine. J. Med. Virol. 17(1), 35–45 (1985).
   PubMedGoogle Scholar
• Henderson BE, Cheshire PP, Kirya GB, Lule M. Immunologic studies with yellow fever and selected African group B arboviruses in rhesus and vervet monkeys. Am. J. Trop. Med. Hyg.19(1), 110–118 (1970).
   PubMedGoogle Scholar
• Theiler M, Anderson CR. The relative resistance of dengue-immune monkeys to yellow fever virus. Am. J. Trop. Med. Hyg.24(1), 115–117 (1975).
   PubMed Web of Science ®Google Scholar
• Sweet BH, Wisseman CJ Jr, Kitaoka M. Immunological studies with group B arthropod-borne viruses. II. Effect of prior infection with Japanese encephalitis virus on the viremia in human subject following administration of 17D yellow fever vaccine. Am. J. Trop. Med. Hyg.11,562 (1962).
   Web of Science ®Google Scholar
• Freestone DS, Ferris RD, Weinberg A et al. Stabilized 17D strain yellow fever vaccine: dose response studies, clinical reactions and effects on hepatic function. J. Biol. Stand. 5(3), 181–186 (1977).
   PubMedGoogle Scholar
• Lopes O de Souza, de Almeida Guimaràes SSD, de Carvalho R. Studies on yellow fever vaccine III dose response in volunteers. J. Biol. Stand. 16(2), 77–82 (1988).
   PubMedGoogle Scholar
• Hacker UT, Jelinek T, Erhardt S et al. In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination. J. Infect. Dis. 177(3), 774–778 (1998).
   PubMed Web of Science ®Google Scholar
• Co MD, Terajima M, Cruz J, Ennis FA, Rothman AL. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 293(1), 151–163 (2002).
   PubMed Web of Science ®Google Scholar
• Gould EA, Buckley A, Cane PA, Higgs S, Cammack N. Use of a monoclonal antibody specific for wild-type yellow fever virus to identify a wild-type antigenic variant in 17D vaccine pools. J. Gen. Virol. 70, 1889–1894 (1989).
   PubMedGoogle Scholar
• Penna HA, Bittencourt A. Persistence of yellow fever virus in brains of monkeys immunized by cerebral inoculation. Science 97, 448 (1943).
   PubMedGoogle Scholar
• Smithburn KC. Immunology of Yellow Fever. In: Yellow Fever Vaccination.Smithburn KC et al. (Eds), World Health Organization, Geneva, Switzerland. 11–27 (1956).
   Google Scholar
• Merlo C, Steffen R, Landis T, Tsai T, Karabatsos N. Possible association of encephalitis and 17D yellow fever vaccination in a 29-year-old traveller. Vaccine 11(6), 691 (1993).
   PubMed Web of Science ®Google Scholar
• Louis JJ, Chopard P, Larbre F. Un cas d’encephalite après vaccination anti-amarile par la souche 17 D. Pédiatrie 36, 539 (1981).
   PubMedGoogle Scholar
• Stuart G. Reactions following vaccination against yellow fever. In: Yellow Fever Vaccination. Smithburn KC et al. (Eds), World Health Organization, Geneva, Switzerland. 143 (1956).
   Google Scholar
• Anon. Fatal viral encephalitis following 17D yellow fever vaccine inoculation. JAMA 198(6), 671–672 (1966).
   PubMedGoogle Scholar
• Ryman KD, Ledger TN, Weir RC, Schlesinger JJ, Barrett AD. Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes. J. Gen. Virol. 78, 1353–1356 (1997).
   PubMedGoogle Scholar
• Barwick RS, Marfin AA, Cetron MS. Yellow fever vaccine-associated disease. In: Emerging Infections. (6th Edition). Scheld WM, Murray BE, Hughes JM (Eds), ASM Press, WA, USA, 25–34 (2004).
   Google Scholar
• Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination–United States, 2001–2002. Morb. Mortal. Wkly Rep. 51(44), 989–993 (2002).
   Google Scholar
• Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX®. Vaccine 22(17–18), 2103–2105 (2004).
   PubMed Web of Science ®Google Scholar
• Vital C, Vital A, Gbikpi-Benissan G et al. Postvaccinal inflammatory neuropathy: peripheral nerve biopsy in 3 cases. J. Periph. Nerve Syst. 7(3), 163–167 (2002).
   PubMedGoogle Scholar
• Voigt U, Baum U, Behrendt W, Hegemann S, Terborg C, Strobel J. Neuritis of the optic nerve after vaccinations against hepatitis A, hepatitis B and yellow fever. Klin. Monatsbl. Augenheilkd. 218(10), 688–690 (2001).
   PubMedGoogle Scholar
• Marchevsky RS, Friere MS, Coutinho ES et al. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys. Virology 316(1), 55–63 (2003).
   PubMedGoogle Scholar
• Kaplan JE, Nelson, DB, Schonberger LB et al. The effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinations. Bull. World Health Organ. 62(4), 585–590 (1984).
   PubMedGoogle Scholar
• Theiler M, Whitman L. Quantitative studies of the virus and immune serum used in vaccination against yellow fever. Am. J. Trop. Med. Hyg.15,347 (1935).
   Google Scholar
• Centers for Disease Control. Notice to readers: fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996–2001. Morb. Mortal. Wkly Rep. 50, 643 (2001).
   PubMedGoogle Scholar
• Marfin AA, Barwick RB, Monath TP. Yellow fever. In: Tropical Infectious Diseases: Principles, Pathogens and Practice. Guerrant RL, Walker DH, Weller PF (Eds), Livingstone, PA, USA (2005) (In Press).
   Google Scholar
• Vasconcelos PFC, Luna EJ, Galler R et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: report of two cases. Lancet 358(9276), 91–97 (2001).
   PubMed Web of Science ®Google Scholar
• Chan RC, Penney DJ, Litele D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 358, (9276) 121–122 (2001).
   Google Scholar
• Adhiyaman V, Oke A, Cefai C. Effects of yellow fever vaccination. Lancet 358 (9296), 1907–1908 (2001).
   PubMed Web of Science ®Google Scholar
• Galler R, Pugachev KV, Santos CLS et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine virus associated with serious adverse events in Brazil. Virology 290, 309–319 (2001).
   PubMed Web of Science ®Google Scholar
• Rodrigues SG, Travassos da Rosa A, Galler R et al. Yellow fever virus isolated from a fatal post vaccination event: an experimental comparative study with the 27DD vaccine strain in the Syrian hamster (Mesocricetus auratus). Rev. Soc. Bras. Med. Trop. 37(Suppl. 2), S69–S74 (2004).
   PubMedGoogle Scholar
• Sawyer WS, Lloyd W. The use of mice in tests of immunity to yellow fever. J. Exp. Med. 54(4), 553–555 (1931).
   Google Scholar
• Brinton MA, Perelygin AA. Genetic resistance to flaviviruses Adv. Virus Res. 60, 43–85 (2003).
   PubMed Web of Science ®Google Scholar
• Lawrence GL, Burgess MA, Kass RB. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun. Dis. Intell. 28, 244–248 (2004).
   PubMedGoogle Scholar
• Barwick RE. History of thymoma and yellow fever vaccination. Lancet 364(9438), 936 (2004).
   PubMed Web of Science ®Google Scholar
• Engels EA, Pfeiffer RM. Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies. Int. J. Cancer 105, 546–551 (2003).
   PubMed Web of Science ®Google Scholar
• Kelleher P, Misbah SA. What is Good’s syndrome? Immunological abnormalities in patients with thymoma. J. Clin. Pathol. 56, 12–16 (2003).
   PubMed Web of Science ®Google Scholar
• Yel L, Liao O, Lin F, Gupta S. Severe T- and B-cell immune deficiency associated with malignant thymoma. Ann. Allergy Asthma Immunol. 91, 501–505 (2003).
   PubMedGoogle Scholar
• Bagnato F, Clemenzi A, Scagnolari C et al. Neutralizing antibodies against endogenous interferon in myasthenia gravis. Eur. Cytokine Netw. 15, 24–29 (2004).
   PubMed Web of Science ®Google Scholar
• Hirsch MS, Murphy FA. Effects of anti-thymocyte serum on 17-D yellow fever infection in adult mice. Nature 216(111), 179–180 (1967).
   PubMedGoogle Scholar
• Kouwenaar W. The reaction to yellow fever vaccine (17D), particularly in allergic individuals. Doc. Med. Geogr. Trop. 5(1), 75–84 (1953).
   PubMedGoogle Scholar
• Kelso J. Raw egg allergy – a potential issue in vaccine allergy. J. Allerg. Clin. Immunol. 106(5), 990 (2000).
   Google Scholar
• Kelso JM, Mootrey GT, Tsai TF. Anaphylaxis from yellow fever vaccine. J. Allerg. Clin. Immunol. 103(4), 698–701 (1999).
   PubMed Web of Science ®Google Scholar
• Nasidi A, Monath TP, Vandenberg J et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans. R. Soc. Trop. Med. Hyg. 87(3), 337–339 (1993).
   PubMed Web of Science ®Google Scholar
• Tsai TF, Paul R, Lynberg MC et al. Congenital yellow fever virus infection after immunization in pregnancy. J. Infect. Dis. 168(6), 1520–1523 (1993).
   PubMed Web of Science ®Google Scholar
• Cetron MS, Marfin AA, Julian KG et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm. Rep. 51, 1–11 (2002).
   PubMedGoogle Scholar
• Pugachev K, Monath TP, Guirakhoo F. Chimeric vaccines against Japanese encephalitis, dengue and West Nile. In: New Generation Vaccines (3rd Edition). Levine M et al (Eds). Marcel Dekker, NY, USA, 559–571 (2004).
   Google Scholar
• Lai CJ, Monath TP. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv. Virus Res. 61, 470–509 (2003).
   Google Scholar
• Jones T. A chimeric live attenuated vaccine against Japanese encephalitis. Expert. Rev. Vaccines 3, 243–248 (2004).
   PubMedGoogle Scholar
• Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 73, 3095–3101 (1999).
   PubMed Web of Science ®Google Scholar
• Arroyo J, Miller C, Catalan J et al. ChimeriVax™-West Nile live-attenuated vaccine: preclinical evaluation of safety, immunogenicity and efficacy. J. Virol. 78(22), 12497–12507 (2004).
   PubMed Web of Science ®Google Scholar
• Fitzner J, Coulibaly D, Ekra Kouadio D et al. Safety of the yellow fever vaccine during the Sepetmber 2001 mass vaccination campaign in Abidjan, Ivory Coast. Vaccine 23, 56–62 (2004).
   Google Scholar
• Monath TP, Cetron M. Prevention of yellow fever in persons traveling to the tropics. Clin. Infect. Dis. 34, 1369–1378 (2002).
   PubMed Web of Science ®Google Scholar
• Monath TP, Nasidi A. Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria. Am. J. Trop. Med. Hyg. 48, 274–290 (1993).
   PubMedGoogle Scholar
• Monath TP, Brinker KR, Chandler FW et al. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the necrosis of B-cell areas of lymph nodes and spleen. Am. J. Trop. Med. Hyg. 30, 431–443 (1981).
   PubMedGoogle Scholar